 
 
Official Title:  Reversing Diabetic Peripheral Neuropathy Through Exercise   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  18-00527  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • March 8, 2022  
 
  
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017   
  
 
 
A cross-over, single -center  study i nvestigating  the effects of e xercise on 
reversing  diabetic peripheral neuropathy  
 
 
Principal Investigator:  
 Ryan Brown , PhD  
Department of Radiology  
660 First Ave., 4th Floor, New York, NY 10016  
Ryan.Brown@nyulangone.org  
212-263-3396  
Additional Investigators:  
 Smita Rao, PT, PhD  
Department of Physical Therapy  
380 Second Ave., 4th Floor, New York, NY 10010  
Smita.Rao@nyumc.org  
212-998-9194 
NYULMC Study Number:  s18-00527  
Funding Sponsor:  National Institutes of Health  
9000 Rockville Pike, Bethesda, MD 20892  
301-496-4000  
ClinicalTrials.gov 
Number                 [STUDY_ID_REMOVED] 
 
Initial version:  July 24, 2018  
Amended version: January 28, 2019  
Amended version: March 20, 2019  
Amended version: December 17, 2019
Amended version: April 22, 2021  
Amended version: February 15, 2022  
 
                  
Study number:  s18-00527   Page ii 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017   
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), any other applicable US government research regulations , and 
institutional research policies and procedures . The Principal Investigator will assure that no deviation from, 
or changes to the protocol will take place without prior agreement from the sponsor and documented 
approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.  
  
Study number:  s18-00527   Page iii 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  Table of Contents   
 
PROTOCOL SUMMARY  .............................................................................................................................. 1 
1 INTRODUCTION, BACKGROUND INFORMATION, AND SCIENTIFIC RATIONA LE ...................... 5 
1.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ................................................................ 5 
1.2 RATIONALE  .................................................................................................................................... 5 
1.3 POTENTIAL RISKS & BENEFITS  ........................................................................................................ 6 
1.3.1  Known Potential Risks  ............................................................................................................. 6 
1.3.2  Known Potential Benefits  ........................................................................................................ 8 
2 OBJECTIVES AND PURPO SE ........................................................................................................... 8 
2.1 PRIMARY OBJECTIVE  ...................................................................................................................... 8 
2.2 SECONDARY OBJECTIVES (IF APPLICABLE ) ...................................................................................... 9 
2.3 EXPLORATORY OBJECTIVE (IF APPLICABLE ) ..................................................................................... 9 
3 STUDY DESIGN AND ENDPOINTS .................................................................................................... 9 
3.1 DESCRIPTION OF STUDY DESIGN  .................................................................................................... 9 
3.2 STUDY ENDPOINTS ......................................................................................................................... 9 
3.2.1  Primary Study Endpoints  ......................................................................................................... 9 
3.2.2  Secondary Study Endpoints  .................................................................................................... 9 
3.2.3  Exploratory Endpoints  ........................................................................................................... 10 
4 STUDY ENROLLMENT AND WITHDRAWAL  .................................................................................. 10 
4.1 INCLUSION CRITERIA  .................................................................................................................... 10 
4.2 EXCLUSION CRITERIA  ................................................................................................................... 10 
4.3 VULNERABLE SUBJECTS  ............................................................................................................... 10 
4.4 STRATEGIES FOR RECRUITMENT AND RETENTION  .......................................................................... 11 
4.4.1  Use of DataCore/Epic Information for Recruitment Purposes  .............................................. 11 
 Use of Craigslist for Recruitment Purposes  ................................................................................... 12 
4.4.2  .................................................................................................................................................... 12 
4.4.3  Direct Advertising  .................................................................................................................. 12 
4.5 DURATION OF STUDY PARTICIPATION  ............................................................................................ 12 
4.6 TOTAL NUMBER OF PARTICIPANTS AND SITES ................................................................................ 12 
4.7 PARTICIPANT WITHDRAWAL OR TERMINATION  ................................................................................ 12 
4.7.1  Reasons for Withdrawal or Termination  ................................................................................ 12 
4.7.2  Handling of Participant Withdrawals or Termination  ............................................................. 12 
4.7.3  Premature Termination or Suspension of Study  ................................................................... 13 
5 BEHAVIORAL/SOCIAL  INTERVENTION  ......................................................................................... 13 
5.1 STUDY BEHAVIORAL OR SOCIAL INTERVENTION (S) DESCRIPTION  .................................................... 13 
5.1.1  Administration of Intervention  ................................................................................................ 13 
5.1.2  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  ................... 14 
6 STUDY PROCEDURES AND SCHEDULE  ....................................................................................... 14 
6.1 SCHEDULE OF EVENTS  ................................................................................................................. 14 
6.1.1  Standard of Care Study Procedures  ..................................................................................... 14 
6.2 LABORATORY PROCEDURES /EVALUATIONS  ................................................................................... 14 
6.2.1  Clinical Laboratory Evaluations  ............................................................................................. 14 
6.3 IMAGING PROCEDURES ................................................................................................................. 15 
6.4 STUDY SCHEDULE  ........................................................................................................................ 15 
6.4.1  Baseline Visit  ......................................................................................................................... 15 
6.4.2  Non- Exercise Phase Visits (4 weeks)  ..................................... Error! Bookmark not defined.  
6.4.3  Post-Non- Exercise Phase Visit  ............................................... Error! Bookmark not defined.  
6.4.4  Maximal Graded Exercise Testing (VO 2R Assessment)  ....................................................... 16 
6.4.5  Exercise Phase (10 weeks)  ................................................................................................... 17 
Study number:  s18-00527   Page iv 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  6.4.6  Post-Exercise Phase Visit  ..................................................................................................... 18 
6.4.7  Withdrawal Visit  ..................................................................................................................... 18 
6.5 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  .................................................... 19 
6.5.1  Precautionary Medications, Treatments, and Procedures  .................................................... 19 
6.6 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ........................................................ 19 
6.7 PROPHYLACTIC MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................................... 19 
6.8 PARTICIPANT ACCESS TO STUDY INTERVENTION AT STUDY CLOSURE  ............................................. 19 
7 ASSESSMENT OF SAFETY  ............................................................................................................. 19 
7.1 SPECIFICATION OF SAFETY PARAMETERS  ...................................................................................... 19 
7.1.1  Definition of Adverse Events (AE)  ......................................................................................... 19 
7.1.2  Definition of Serious Adverse Events (SAE)  ......................................................................... 19 
7.1.3  Definition of Unanticipated Problems (UP)  ............................................................................ 20 
7.2 CLASSIFICATION OF AN ADVERSE EVENT  ....................................................................................... 20 
7.2.1  Severity of Event  ................................................................................................................... 20 
7.2.2  Relationship to Study Intervention ......................................................................................... 20 
7.2.3  Expectedness  ........................................................................................................................ 20 
7.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP .................................... 21 
7.4 REPORTING PROCEDURES – NOTIFYING THE IRB .......................................................................... 21 
7.4.1  Adverse Event Reporting  ...................................................................................................... 21 
7.4.2  Unanticipated Problem Reporting  ......................................................................................... 21 
7.4.3  Reporting of Pregnancy  ......................................................................................................... 22 
7.5 SAFETY OVERSIGHT  ..................................................................................................................... 22 
8 DATA SAFETY MONITORI NG PLAN  ............................................................................................... 22 
9 STATISTICAL CONSIDER ATIONS  .................................................................................................. 23 
9.1 STATISTICAL AND ANALYTICAL PLANS  ........................................................................................... 23 
9.2 STATISTICAL HYPOTHESES  ........................................................................................................... 23 
9.3 DESCRIPTION OF STATISTICAL METHODS  ...................................................................................... 23 
9.3.1  General Approach  ................................................................................................................. 23 
9.3.2  Analysis of the Primary Efficacy Endpoint(s)  ........................................................................ 23 
9.3.3  Analysis of the Secondary Endpoint(s)  ................................................................................. 24 
9.3.4  Adherence and Retention Analyses  ...................................................................................... 24 
9.3.5  Baseline Descriptive Statistics  .............................................................................................. 24 
9.3.6  Exploratory Analyses  ............................................................................................................. 24 
9.4 SAMPLE SIZE ............................................................................................................................... 24 
10 SOURCE DOCUMENTS AND ACCESS TO SOURCE DA TA/DOCUMENTS  ................................. 25 
11 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ............................................................................. 25 
11.1  ETHICAL STANDARD  ..................................................................................................................... 25 
11.2  INSTITUTIONAL REVIEW BOARD  ..................................................................................................... 25 
11.3  INFORMED CONSENT PROCESS  .................................................................................................... 26 
11.3.1  Consent/Assent and Other Informati onal Documents Provided to Participants  ............... 26 
11.3.2  Consent Procedures and Documentation  ......................................................................... 26 
11.4  PARTICIPANT AND DATA CONFIDENTIALITY  .................................................................................... 26 
11.5  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  .............................................................. 27 
11.6  STUDY RECORDS RETENTION  ....................................................................................................... 27 
11.7  PROTOCOL DEVIATIONS  ............................................................................................................... 27 
12 STUDY FINANCES  ............................................................................................................................ 27 
12.1  FUNDING SOURCE  ........................................................................................................................ 27 
 COSTS TO THE PARTICIPANT  ................................................................................................................. 27 
12.2 ......................................................................................................................................................... 27 
12.3  PARTICIPANT REIMBURSEMENTS OR PAYMENTS  ............................................................................ 27 
13 CONFLICT OF INTEREST  POLICY  .................................................................................................. 28 
Study number:  s18-00527   Page v 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  14 REFERENCES  ................................................................................................................................... 28 
ATTACHMENTS  ......................................................................................................................................... 32 
 
  
Study number:  s18-00527   Page vi 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017   
List of Abbreviations  
 
ACSM  American College of Sports Medicine  
AE Adverse Event  
BMI Body Mass Index  
CBI Center for Biomedical Imaging  
CFR Code of Federal Regulations  
CRF Case Report Form  
DM Diabetes Mellitus  
DPN  Diabetic Peripheral Neuropathy  
DTI Diffusion Tensor Imaging  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ITT Intention to Treat  
IRB Institutional Review Board  
MNSI  Michigan Neuropathy Screening Instrument  
MRI Magnetic Resonance Imaging  
MV Microvascular  
MVC  Maximum Voluntary Contraction  
NIH National Institutes of Health  
OGTT  Oral Glucose Tolerance Test  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
RPE Rate of Perceived E xertion  
ROS  Reactive Oxidative Species  
SAE Serious Adverse Event/Serious Adverse Experience  
T2DM  Type 2 Diabetes Mellitus  
US United States  
VO 2R Maximal Graded Exercise Test  
 
 
    
 
Study number:  s18-00527   page 1    
Version: February 15, 2022  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by the study sponsor 
Drug/Device Template Version: 13 JUN 2016  Protocol  Summary 
Title A cross -over, single -center study investigating the effects of exercise on 
reversing diabetic peripheral neuropathy  
Short Title  Reversing diabetic peripheral neuropathy through exercise 
Brief Summary  This project proposes a longitudinal  design that uses multinuclear -MRI to 
evaluate the mechanistic effects of exercise on skeletal muscle function and 
peripheral nerve integrity in patients with diabetic peripheral neuropathy 
(DPN), and to determine whether exercise can reverse DPN symptoms.  We 
will prescribe a 10- week exercise program to 40 DPN patients . We will 
acquire multinuclear -MRI data before and after the intervention that can 
provide mechanistic insight into the adaptations in lower leg muscle function 
and peripheral nerve integrity of patients with DPN , and their role in 
improving DPN symptoms following physical exercise intervention.  
Phase  N/A 
Objectives  Objective 1: Determine the effect of exercise on peripheral nerve 
architecture, function, and symptoms of DPN.  
Objective 2: Determine the effect of exercise on lower leg muscle structure 
and function in DPN patients.  
Methodology  Longitudinal  design  
Endpoint  Body mass index (BMI), glycosylated hemoglobin (HbA1c), and C -reactive 
protein will be assessed before and after the 10- week intervention, along with 
the following measures of neuropathic symptoms : 1) Michigan Neuropathy 
Screening Instrument (MNSI) symptom questionnaire and the PROMIS 
physical function and fatigue questionnaire, 2) MNSI physical exam score, 3) Vibration Perception Threshold (VPT) and Calf Muscle performance,  4) 
Plasma levels hydrogen peroxide as marker of ROS , 5) Lower leg muscle 
performanc e (9-item Physical Performance Test) , activity monitor with 
actigraph, and 6) Multinuclear MRI will assess changes in muscle function 
and peripheral nerve integrity. 7) Utah Early Neuropathy Scale, which is a 
physical exam specific to early sensory predomi nant polyneuropathy.  
Study Duration  2 years  
Participant Duration  ~10 weeks  
Duration of behavioral 
intervention  10 weeks  
Population  40 patients with Type 2 diabetes  and clinical symptoms of DPN  (both male 
and female) between the ages of 40 -70 years old  
Study Sites  Single -center  
Number of participants  40 participants expected to be enrolled across one site  
Description of Study 
Intervention/Procedure  A 10-week exercise program wit h both aerobic and resistance  components, 
based on the American College of  Sports Medicine (2010), will be individually 
prescribed to 40 DPN patients . Prior to beginning the intervention, subjects 
will participate in a maximal graded exercise test  (VO 2R) using a cycle 
ergometer with a metabolic cart and integrated ECG.  
Reference Therapy  N/A  
Key Procedures  Oral Glucose Tolerance Test (OGTT), multinuclear -MRI, VO 2R, MNSI , 
physical therapy, activity monitor  
Study number:  s18-00527   Page 2 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  Statistical Analysis  The analysis will follow the intention -to-treat (ITT) princip le and include data 
from every subject irrespective of whether the subject was compliant with the 
intervention. A quantitative assessment of compliance with the intervention, 
ranging from 0 (complete non- compliance) to 1 (full compliance), will be 
included as a weighting factor to allow more compliant subjects to contribute 
more to the analysis.  
 
 
  
Study number:  s18-00527   Page 3 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  Flow diagram  (longitudinal  design)  
 
 
Recruit a total of 40 participants : contact potential participants  via phone/email , 
MyChart , or in person to perform prescreening by inclusion/exclusion criteria  
Perform baseline assessments: Informed consent, MRI, blood draw, OGTT, administer 
actigraph to patient  
(Blood draw will be perform at CBI or at TISCH Outpatient Lab)  
 
10-week intervention phase (3- 4 days/week):   
Aerobic exercise: 30- 50 mins of 50% VO 2R x 2 days  
Resistance exercise: 10- 20 reps x 1- 2 days  
Prior to 
Enrollment  
Baseline  
Intervention  
Intervention 
follow -up 
Post 10 -week exercise phase: Blood draw , OGTT, and MRI  
(Blood draw will be perform at CBI or at TISCH Outpatient Lab)  
 
CBI 
CBI  
 
Pre-exercise testing: VO 2R 
Post-MRI 
LOC 
 
Post-exercise testing: VO 2R 
Post-MRI 
LOC 
CBI  
PT Center  
Study number:  s18-00527   Page 4 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  Key Roles  
 
Ryan Brown, PhD, Principal Investigator  
NYU Langone Health  
Center for Biomedical Imaging; 660 First  Ave., New York, NY 10016 
212-263-3396  
Ryan.Brown@nyulangone.org  
 
Smita Rao, PT, PhD, Co- Principal Investigator  
NYU Steinhardt Department of Physical Therapy  
380 Second Ave., 4th Floor, New York, NY 10010  
212-998-9 194 
Smita.Rao@nyumc.org  
  
 
     
 
     
 
    
 
     
 
     
 
     
 
 
Study number:  s18-00527   Page 5 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  1 Introduction, Background Information, and Scientific Rationale  
This document is a protocol for a human research study. This study is to be conducted in accordance with 
US government research regulations, applicable international standards of Good Clinical Practice, and institutional research policies and procedures.  
1.1 Background Informati on and Relevant Literature  
Diabetes mellitus (DM) affects 26 million people in the US [1] with 30 –50% of Type- 2 Diabetes Mellitus 
(T2DM) patients developing diabetic peripheral neuropathy (DPN) [2 -4]. DPN is characterized by 
impairments of metabolic and microvascular (MV) functions [5] , which damage the endoneural capillaries 
that supply the peripheral nerves [6]. Prolonged DPN can lead to local ischemic conditions in the lower 
extremities, causing loss of peripheral nerve integrity, neurogenic muscle atrophy, fatty infiltration [7, 8] , 
and loss of muscle endurance [9 -12]. These synergistically contribute to altered gait, impaired balance, 
and increased fall risk, which can lead to bone fractures, poorly healing wounds, and chronic infections [13-15]
 that often require an amputation [16, 17]. There are no therapies to prevent or reverse the 
progress of DPN [18- 20]. Therefore, it is very important to establish effective treatments  for DPN.  
 A growing body of literature supports the benefits of combining moderate- intensity aerobic exercise with resistance training to improve 
glycemic control and insulin sensitivity in individuals with DM [21, 22] . 
However, little is known about the benefits of exercise in individuals 
with DPN. Preliminary single -group studies conducted by Dr. Kluding 
(co-investigator) have shown that a moderate intensity supervised 
exercise significantly improve their cardiorespiratory function, and can 
also improve DPN symptoms, including nerve function and cutaneous 
innervation (Fig. 1) [23, 24]. In addition, exercise can improve vascular 
endothelial function in DPN [25] . Non- invasive exercise intervention is 
particularly valuable in this population due to its safety, low cost, and potential to augment pharmacological interventions. Our longitudinal  
study design seeks to understand the effects of exercise in skeletal 
muscle fu nction and peripheral nerve integrity of DPN patients. We 
hypothesize that exercise can partially reverse DPN progression 
because it promotes MV dilation, reduces oxidative stress, and increases the abundance of neurotrophic factors, all of which are compr omised in DPN [26] . Exercise will be able to improve lower limb 
muscle function by inhibiting key metabolic pathways that cause 
hypoxia. Successful completion of our study will facilitate the 
development of mechanism -based intervention strategies for 
individuals with DPN.   
1.2 Rationale  
Hyperglycemia is an important factor  in the development of DPN. However, the pathophysiological 
processes through which hyperglycemia causes DPN are not fully understood. Furthermore, large clinical 
studies (ACCORD [27] , ADVANCE [28], VADT [29] ) have shown that good glucose control is insufficient 
to reduce the occurrence of foot complications, including DPN and diabetic foot ulcers. There are no Food 
and Drug Administration (FDA) -approved treatment options that target the underlying pathogenesis of 
DPN [19, 30] . Therefore, it is important to establish strategies to delay or reverse the effects of DPN.  
 We hypothesize that DPN patients who undergo 10 weeks of exercise will show improved peripheral 
nerve integrity and function, and that exercise will improve the structure, local metabolic, and MV 
functions of skeletal muscle. A major obstacle to assessing how DPN affects skeletal muscle and peripheral nerves is the lack of sensitive, objective, and reproducible tests to detect small changes in muscle and nerve functions [10] . Multinuclear -MRI can bring new insights into how DPN affects skeletal 
muscle function and peripheral nerve integrity [31 -33]. Our group has developed novel phosphorus (31P) -
MRI techniques that can reliably assess skeletal muscle metabolic function [34, 35] ,
 as well as rapid  
Figure 1 . Effects of Exercise on 
Cutaneous Innervation in DPN 
Patients . Skin biopsy from a DPN 
patient before ( A) and after ( B) 10 
weeks of exercise. Intraepidermal 
nerve fibers are significantly 
denser (arrows) after the exercise 
intervention.  
 

Study number:  s18-00527   Page 6 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  techniques to quantify blood oxygenation level dependent (BOLD) -MRI signals, sensitive to MV function 
[36-38] and its adaptations after exercise interventions [39]. In addition, we will use diffusion tensor 
imaging (DTI), a powerful MRI technique, to quantitatively assess neuronal integrity and detect nerve 
injury and monitor reinnervation [40 -46]. The use of DTI will allow us to non- invasively assess peripheral 
nerve adaptations after exercise intervention. Finally, we will use IDEAL- MRI to quantify levels of 
intramuscular adipose tissue (IMAT), which are elevated in DPN [47- 50]. We will prescribe a 10 -week 
exercise program, with both aerobic and resistance components [14, 24] , to 40 DPN patients who will 
receive personal supervision from health professionals. We will acquire multinuclear -MRI data at three 
time points: 1) baseline, 2) pre- intervention and 3) post -intervention. We will measure plasma levels of 
reactive oxidative species (ROS) as markers of oxidative stress.  
 Like all longitudinal studies, exercise intervention studies are at risk of losing participants who choose to discontinue their participation during the intervention. Our team has developed effective strategies to promote high levels of adherence even with this challenging population, with our preliminary studies 
showing low attrition rates [23, 24]. Our previous experience with intervention studies indicates that the 
main reason patients discontinue participation is the cost associated with travel (bridge/tunnel tolls, parking, bus, and taxi fare). Therefore, we have budgeted funds to offset transportation expenses for participants (up to $20 per visit). To further convenience our participants, we will offer flexible scheduling for appointments in our research dedicated physical therapy center (380 2
nd Ave), including availability 5-
days/week and 12- hrs/day (from 8am to 8pm). In the current proposal, data analysis will follow the ITT 
principle and include data from every subject regardless of whether the subject complied with the 
intervention.  
1.3 Potential Risks & Benefits 
1.3.1  Known Potential Risks  
There are two categories of risk associated with this study:  
 
1) T he potential risks resulting from physical exercise.  
 Qualified, attending medical personnel will categorize the test outcomes (including post -test events) as 
one of the following, using the criteria that follow:  
 
a) Benign events that fall within the "normal" set of outcomes for the tests;  
b) "Abnormal" outcomes that do not, by themselves, warrant termination of the exercise and that do not 
cause the subject to stop exercise or complain; or  c) Adverse Events or Serious Adverse Events that are not "normal" outcomes, that warrant termination of 
the exercise, or that cause the subject to complain or terminate the exercise of their own volition.  
 In Type c  events, the exercise will be immediately terminated.
 As needed, participants will receive on- site 
medical treatment, referral to hospital for immediate follow -up care, or a call will be placed for Emergency 
Medical Services (EMS), transport to hospital, and emergency treatment. Except where EMS are 
involved, t he subject will be asked to stay at the testing lab for observation for at least half an hour after 
his or her condition is stable.  
 
In all Type c  cases, the research staff will attempt to contact the subjects' personal physician (or the 
person covering his or her practice, as available) by phone, to apprise him or her of the exercise outcome 
and the treatment given. Except where EMS are involved, this first phone call will be made after the subject is stable and before the subject leaves the testing lab. If no person- to-person contact can be 
made with the subject's physician (or their substitute) within this time frame, this fact will be documented and repeated attempts will be made and documented until contact is made.  
 
Within 48 hours of the test, for both Type b and Type c  events, the outcomes, treatments, and 
documentation of phone calls and other correspondence (e.g., with EMS) will be described in a written report to the subject's personal physician. The subject will also receive a copy of the report . 
Study number:  s18-00527   Page 7 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017   
Individuals experiencing Type a and Type b events will be supervised until their symptoms resolve. The 
event will be documented. Subsequent exercise sessions will be monitored to prevent recurrence of 
adverse event.  
 
Criteria for Categorizing Exercise A dverse Events  
Type b Indications —"Abnormal" outcomes that do not, by themselves, warrant terminating the exercise 
test, such as occasional premature beats at rest and which are more frequent with exercise, or the appearance of a new but non- sustained arrh ythmia.  
Type c Indications —Adverse Events or Serious Adverse Events that should result in terminating the 
exercise.  
 
Exercise Standards for Testing and Training from the American Heart Association will be used to define absolute and relative contra- indica tions to exercise testing [51] . 
 
Absolute Indications  
• Acute myocardial infarction (MI), within 2 days  
• Ongoing unstable angina  
• Uncontrolled cardiac arrhythmia with hemodynamic compromise 
• Active endocarditis  
• Symptomatic severe aortic stenosis  
• Decompensated heart failure 
• Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis  
• Acute myocarditis or pericarditis  
• Acute aortic dissection  
• Physical disability that precludes safe and adequate testing  
 
Relative Indications  
• Known obstructive left main coronary artery stenosis  
• Moderate to severe aortic stenosis with uncertain relation to symptoms  
• Tachyarrhythmia with uncontrolled ventricular rates  
• Acquired advanced or complete heart block  
• Hypertrophic obstructive cardiomyopathy with severe resting gradient  
• Recent stroke or transient ischemic attack  
• Mental impairment with limited ability to cooperate  
• Resting hypertension with systolic or diastolic blood pressures >200/110 mm Hg 
• Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, and 
hyperthyroidism  
 
Additionally, to minimize the risk of ulcer development in the “high risk” foot, we will inspect participants’ feet weekly . 
 
2) R
isks that are incurred by the performance of MR imaging. All subjects will be screened 
for the same potential hazards as routine clinical patients (see below) and those subjects 
at risk will not be imaged.  
 
This research study involves the use of newly  developed imaging hardware and software at 3T. The 
human subjects will be scanned using an FDA -approved 3.0 Tesla MRI scanner. A standard MRI safety 
form will be used for subject eligibility. All new technologies used in this investigation meet or surpass  the 
safety standards of the FDA and are considered non- significant risk as defined in the “Guidance for 
Industry and FDA Staff – Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic 
Devices” issued July 14, 2003. According to the Blue Book memorandum entitled “Significant Risk and Non- significant Risk Medical Device Studies”, magnetic resonance devices operating within FDA 
guidelines up to 8T are considered non- significant risk.   
 
Study number:  s18-00527   Page 8 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017   
All subjects will be screened for biomedical implants and devices through questioning at the time of 
recruitment to the study, as well as on the day of the examination. Subjects with potentially MR 
incompatible devices or other hazards, such as orbital foreign bodies, will be excluded. If pregnancy is a possibility, female subjects will undergo a urine test on the day of the MR examination. If the test is 
positive, then the subject will be excluded from the study. During the MRI experiments, the MRI scanner will monitor the radiofrequency (RF) power deposition. If it detects any sequence parameters that exceed the allowed RF power limits, it will automatically stop the sequence and a message will be displayed 
indicating that the sequence cannot be run as it exceeds the power deposition limits. This will eli minate 
the risk associated with inadvertent errors during scanning time. All subjects will be pre- screened by the 
study coordinator or research data associate over the phone. The MRI technician will screen all subjects 
at the time of the MR examination.  
 
Medical Facilities and Data Management:  All imaging will be performed at the Department of 
Radiology. The supervised exercise program will be performed at the Arthur J. Nelson Jr. Human 
Performance Lab at NYU’s Department of Physical Therapy. Both centers are staffed by licensed care providers with CPR certification. All patients enrolled will be required to confirm that they are neither pregnant nor have pacemakers, cerebral aneurysm or other clips. Subjects with pacemakers, clips or metals, or who are claustrophobic will be excluded from the study. To further ensure patients against potential risks, all data will be anonymized as part of standard clinical management. Data specifically 
derived from all MRI scans will be anonymized, performed on a stand- alone research workstation with no 
connections to radiologic or hospital records, and correlated independently with appropriate clinical data 
so as to ensure that they will not interfere with ongoing patient management. All patient MRI scans will be stored electronically and accessed via a NYU MCIT -platform.. All clinical and exercise -related data will be 
de-identified and stored on a password protected server at the Arthur J. Nelson Jr. Human Performance 
Lab at the Department of Physical Therapy. All informed consents and paper documents will be stored in a locked file cabinet and room with access given only to authorized study personnel.  
1.3.2  Known Potential Benefits 
While there are no direct benefits to the patients for participating, the complete medical evaluation will be 
of general value since previously unknown medical problems may be detected. In addition, individuals 
who have diminished glucose regulation will be informed of these results, so that they can notify their personal physicians and have this monitored more closely. These individuals will be given advice on measures they can take to improve their peripheral glucose regulation, such as diet. Our licensed physical therapist will offer our subjects nutrition guidelines from the American Diabetes Association. The 
exercise tests may provide participants with information about their current state of health and physical 
fitness. The information may also be helpful in developing or altering an exercise program to enhance their physical fitness. The benefit to society will be the establishment of the efficacy of physical exercise 
on improving DPN symptoms, and by using advanced multinuclear MRI metrics to provide mechanistic insight into the exercise- associated adaptations in MV and metabolic functions.  
 
Risk/Benefit Assessment:  Although the potential benefits from participation in this study will be minimal 
for the individual subjects, the risks are minimal as well. In view of the potential benefits to society of 
establishment of the efficacy of physical exercise on improving DPN symptoms, the overall risk/benefit is favorable.  
2 Objectives and Purpose  
2.1 Primary Objective  
The primary objective is to assess and compare the interventions (exercise versus control phase) in terms of the baseline to follow -up change in the following outcomes: 1) DTI, plasma ROS level, and the MNSI 
assessment of DPN symptoms (Aim 1); and 2) leg mitochondrial function, oxidative capacity (31P -MRI), 
peak MV response (BOLD -MRI), the proportion of fat -free muscle (IDEAL- MRI) and leg muscle strength 
(Aim 2).  
Study number:  s18-00527   Page 9 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  2.2 Secondary Objectives (if applicable)  
NA 
2.3 Exploratory Objective (if applicable)  
The exploratory objective is to identify baseline factors (e.g., age, MNSI, general activity) predictive of 
improvement, represented as the baseline to follo w-up change in each outcome. This objective will be 
addressed using linear regression and bivariate correlations.  
3 Study Design and Endpoints  
3.1 Description of Study Design  
This single -center, longitudinal  design study uses multinuclear -MRI to evaluate the mechanistic effects of 
exercise on skeletal muscle function and peripheral nerve integrity in patients with DPN , and to determine 
whether exercise can reverse DPN symptoms. Forty DPN patients will be enrolled and be prescribed a 
10-week exercise program  following a 4- week non- exercise period. The exercise program w ill comprise 
aerobic and resistance components; a moderate level of intensity will be calculated based on results from 
a maximal graded exercise test (VO 2R) conducted prior to the intervention. Multinuclear -MRI data will be 
acquired at baseline, as well as before and after the intervention that can provide mechanistic insight into 
the adaptations in lower leg muscle function and peripheral nerve integrity of patients with DPN , and thei r 
role in improving DPN symptoms . 
3.2 Study Endpoints  
3.2.1  Primary Study Endpoints 
Body mass index (BMI), glycosylated hemoglobin (HbA1c), and C -reactive protein will be assessed 
before and after the 10- week intervention, along with the following m easures of neuropathic symptoms:  1) 
MNSI symptom questionnaire with yes/no responses to 15 items indicat ing the frequency and severity of 
neuropathic symptoms and Patient -Reported Outcomes Measurement Information System  (PROMIS) 
Physical Function and F atigue subscales, which are computer adaptive tools, will be used to assess 
symptoms related to physical disability and fatigue [52]; 2) MNSI physical exam score, to indicate 
abnormalities in the appearance of the feet, vibration sense, reflexes, and monofilament sensation;  3) 
Vibration Perception Threshold (VPT) will be assessed on the plantar aspect of the great toe [53]  and Calf 
Muscle performance will be quantified as peak ankle plantarflexion torque at 60 degrees/ sec [54]; 5) 
Plasma levels hyd rogen peroxide as marker of ROS;  6) Lower leg muscle performance will also be 
assessed using the  9-item Physical Performance Test  [54]; and 7)  the Utah Early Neuropathy Scale, 
which is a physical exam specific to early sensory predominant polyneuropathy.  Physical activity will be 
quantified using a wearable activity monitor (actigraph) [55] . Subjects will be required to wear the 
actigraph for at least a week.  
 T
he following outcomes will be assessed through multinuclear -MRI: 1) PCr resynthesis rate in the 
gastrocnemius (G) and the soleus (S) muscle groups, following a 90- s plantar flexion exercise during 
which resistance is applied at approximately 40% of the individual’s maximum voluntary contraction 
(MVC); 2) Time -to-peak (TTP) of the BOLD signal in the G and S muscle groups; 3) Peak ΔT2* at 100% 
isometric MVC in the G and S muscle groups; 4) IMAT in the G and S muscle groups using IDEAL MRI; 5) Fractional anisotropy (FA) in the tibial nerve using DTI; 6) Apparent diffusion coefficient (ADC) in the 
tibial nerve using DTI . 
3.2.2  Secondary Study Endpoints  
NA 
Study number:  s18-00527   Page 10 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  3.2.3  Exploratory Endpoints 
Identification of baseline factors (e.g., age, MNSI  [56], general activity) predictive of improvement, 
represented as the baseline to follow -up change in each outcome. 
4 Study Enrollment  and Withdrawal 
4.1 Inclusion Criteria  
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
1. Be 40 -70 years old  
2. Have a clinical diagnosis of Type 2 diabetes  
3. Have clinical symptoms of DPN potentially including lack of monofilament and vibration 
perception  
4. Have a BMI less than 40 kg/m2 (due to magnet bore restrictions)  
5. Be vaccinated for COVID -19  
 
4.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. Serious cardiac pathology or musculoskeletal problems that would limit exercise ability  
2. MNSI score < 1  
3. Current open wound or history of plantar ulcer for the last 3 months  
4. Stroke or other central nervous system pathology 
5. Stage 2 hypertension (resting blood pressure >160 systolic or >100 diastolic)  
6. Contraindications to 3T whole body MRI scanners (e.g., pacemaker, cerebral aneurysm clip, cochlear implant, presence of shrapnel in strategic locations, metal in the eye, claustrophobia, or 
other problems).  
7. Subjects with alcoholism, chronic drug use, chronic gastrointestinal disease, or renal or hepatic impairment  
8. Pregnant women and children  
4.3 Vulnerable Subjects  
Diabetes affects approximately 26 million people in the US and although prevalence may differ among 
different races and ethnicities, no population is spared. Age and sex -adjusted rates for diabetes by race 
have been reported as: Asian Americans 8.4%, non- Hispanic whites 7.1%, Hispanic/Latinos 12.6%, non-
Hispanic blacks 15.3%, American Indians/Alaska natives 14.2%. From those diagnosed, 49% are women 
and 51% are men. Our targeted/planned subject enrollment will reflect the diverse racial and ethnic patient population that is served by the NYU Hospitals’ system. This system functions as one of the main 
referral centers for lower Manhattan, Queens, and Brooklyn.  
 DPN is one of the most common complications of T2DM. Nerve damage in DPN is likely due to combination of factors including high blood glucose, long duration of  diabetes, and abnormal fat levels. It 
is generally accepted that among children with T2DM, DPN is very rare. Therefore, children will be excluded from this study.  
 If a volunteer is an employee, student, or resident of NYU Langone Health or its affiliates , their decision to 
participate, decline participation, or withdraw from the study will have no impact on the individual’s employment, academic standing, or grades. Record of the participation cannot be linked to an academic 
record.  
 
The justification for enrolling this population is due to the strict inclusion/exclusion criteria we have for this 
study. We are not directly targeting the recruitment of NYU students/employees, however, if we come across a n eligible candidate who is an NYU student/employee, we want to be able to enroll him/her into our 
Study number:  s18-00527   Page 11 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  study. Recruitment is conducted by the PIs, research coordinator(s), and other study team members . 
Anyone who recruits or consents for this study has no role in grading or evaluating students.  
  
The consent process is conducted in a private room where the study procedures and risks are explained to the subject. A photocopy of the signed consent  form is given to the subject. The consent process is 
appropriate for the research being conducted. Often times an eligible patient’s treating physician is called to ask if the physician objects to study participation for the patient. This extra screening step is done for the purpose of maximizing protection against risks and minimizing any coercion.  
 This study consists of multiple visits which allow the study team the opportunity to frequently discuss with the subject that his/her participation is voluntary. In order to ensure this is done, the study’s case report forms include a task to remind the participant that withdrawal from the study is possible at any time. In order to minimize breaches of confidentiality, all participants are assigned a subject ID number upon study enrollment. The ID number is not associated with the subject’s name or any other identifying informati on. 
Only the subject’s ID and initials are used when collecting and recording data. The case report forms and source documentation are kept in a binder that is stored in a locked cabinet, in a locked room. Only Radiology Department staff have the code to the room with the binders.  
 
4.4 Strategies for Recruitment and Retention  
Participants who meet our study’s criteria will be recruited from collaborating clinics at NYULH, DataCore 
at NYU, through direct advertising via social media (Craigslist) or brochures/flyers, and from existing 
relationships with prior research subjects. Interested individuals will complete a structured telephone screening and/or online eligibility screening survey. Eligible individuals will be invited to participate in the study.  
 Our recruitment methods/materials may include a link to an online eligibility screening survey. The content 
of the survey will be submitted to the IRB for approval. PHI will be collected as a result of completing the 
screening form. If the subject is not eligible to participate, PHI will be destroyed immediately.  
4.4.1  Use of DataCore/Epic Information for R ecruitment Purposes  
This study will utilize  DataCore and EPIC for recruitment purposes . DataCore will be used to generate a 
report of potential participants that meet this study’s eligibility criteria. Additionally, study team member(s) will perform weekly EPIC screenings of patients at collaborating NYULH clinics until target enrollment is achieved.  
 The following data points and PHI will be used:  
• First and last nam e 
• Contact information  
• Clinical diagnoses and medications  
• Office visit notes  
• Medical Record Number (MRN)  
• Treating Physician (TP)  
 The IRB -approved study personnel who will have access to the EPIC  search results  are the following:  
• Principal Investigator  
• Co-Investigator  
• Study Coordinator  
• Research Coordinator  
• Research Data Associate  
 Once potential subjects have been identified, they will be contacted in one of the following ways:  
Study number:  s18-00527   Page 12 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  • The TP will be notified by email or in person that they have an eligible patient. He/she may tell the 
patient about this research opportunity and may provide recruitment materials. He/she may also obtain the patient’s permission to be contacted by study staff (in person or by telephone).  
• The study team may access contact information from medical records through DataCore to contact patients directly.  
• They may receive an approved recruitment message to their MyChart account.  Recipients can 
respond to indicate whether they are interested in participating.  
 If a subject requests information regarding opting out of further recruitment for all research, subjects will be directed to contact research- contact -optout@nyumc.org or 1- 855-777-7858.  
 
4.4.2  Use of Craigslist for Recruitment Purposes  
Craigslist will be used for recruitment. The ad will be posted under “community > volunteers.” The language in the ad will be submitted to the IRB for approval.  
4.4.3  Direct Advertising  
Our team will use brochures, flyers, and other IRB -approved recruitment materials to provide information 
to interested individuals. We plan to distribute recruitment materials in spaces that we expect our target population to frequent. We will seek approval from the establishment or facilities management prior to posting. Locations that we expect to distribute to include, but are not limited to, collaborating NYULH clinics and physicians, private non- NYULH clinics (i.e. local podiatry clinics), residential buildings, senior 
centers, libraries, community centers, etc.  
4.5 Duration of Study Participation  
Participants will be enrolle d for a minimum of 10 weeks. We anticipate that some participants will be 
enrolled for greater than 10 weeks due to challenges associated with scheduling study procedures 
(limited availability on the MRI scanners). Additionally, we are allowing a one- week grace period during 
the intervention for patients who express pain/soreness due to the exercise regimen, or for other 
circumstances (i.e., planned vacation).  
4.6 Total Number of Participants and Sites  
Recruitment will end when approximately 40 participants a re enrolled across one site.  
4.7 Participant Withdrawal or Termination  
4.7.1  Reasons for Withdrawal or Termination  
Participants are free to withdraw from participation in the study at any time upon request. An investigator 
may terminate participation in the study if: 
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
participant  
• The participant meets an exclusion criterion (ei ther newly developed or not previously 
recognized) that precludes further study participation  
4.7.2  Handling of Participant Withdrawals or Termination  
If a participant misses an intervention session, they will be contacted by study personnel and reasons for 
missing the session will be documented. We will seek written permission to contact participants and will 
reach them using their  preferred method (phone or email). If attendance drops below 80%, 
reimbursement will be pro- rated based on the number of sessions completed. Participants  will be allowed 
a grace period/extension of one week. If participants miss more than one consecutive week, participation will be considered terminated.    
 
Study number:  s18-00527   Page 13 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  If a participant chooses to withdraw from the exercise intervention, they will  be contacted by study 
personnel and reasons for withdrawal  will be documented. We will seek written permission to contact 
participants and will reach them using their preferred method (phone or email). Reasons for withdrawal 
will be classified as related or unrelated to intervention. Participants will be invited to complete endpoint 
testing even if they choose to withdraw from the intervention.  
 Participants that cannot complete the study due to incompatible logistics (precipitating from i.e. covid-relate d study suspension or personal leave of absence) will be encouraged to continue the study at a 
later date. Participants with long- term absences will be re- consented and will re- perform all study 
procedures in the longitudinal protocol described in section 6. Such participants will be considered newly enrolled and must meet all inclusion/exclusion criteria laid out in section 4. Long- term absence is defined 
as: 1) greater than 3- months between Step 2: Blood draw (section 6.4.1.2) and Post -non-exercise phase 
visit (section 6.4.3) or 2) greater than 4- months  between Post -non-exercise phase visit (section 6.4.3) and 
Post-exercise phase visit (section 6.4.6).  
4.7.3  Premature Termination or Suspension of Study 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided 
by the suspending or terminating party to the NIH. If the study is prematurely terminated or suspended, 
the P I will promptly inform the IRB and will provide the reason(s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to par ticipants  
• Demonstration of efficacy that would warrant stopping  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Determination of futility  
 Study may resume once concerns about safety, protocol compliance, and data quality are addressed and satisfy the sponsor and/or IRB.  
5 Behavioral/Social Intervention 
5.1 Study Behavioral or Social Intervention(s) Description  
We propose to combine moderate intensity aerobic exercise with lower -extremity specific resistance 
training, which is expected to reverse DPN symptoms. While current ADA (Americans with Disabilities 
Act) and American College of Sports Medicine (ACSM) guidelines emphasize the benefits of combination 
(i.e., aerobic and resistance) training programs, there is significant heterogeneity in the duration, intensity, frequency and specific exercises used in resistance training programs. Since DPN is length- dependent, 
distal extremities are more severely affected [57] . While most previous studies have assessed thigh 
skeletal muscle, we will assess the plantar flexors. Previous studies have demonstrated that significant impairments exist in lower extremity muscles in individuals with DPN, most notably lower plantar flexor 
strength and flexibility [58, 59]. Therefore, we expect an exercise intervention that combines aerobic 
training and strength training of the lower extremity will further reverse DPN symptoms.  
5.1.1  Administration of Intervention 
The exercise intervention will be administered in person at NYU’s Department of Physical Therapy, 380 
2nd Ave. The site PI (Smita Rao) and Research Associate will supervise all procedures. Health 
professional students may assist Dr. Rao and the Research Associate. The 10- week intervention has 
been previously published [24]  and will include 3 days a week of moderate intensity aerobic and 
resistance training. Each session will last 60 -90 minutes.  
Study number:  s18-00527   Page 14 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  5.1.2  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  
The exercise intervention will be administered by licensed physical therapists or health professionals with 
exercise training. Each participant will follow a previously published 10- week moderate intensity aerobic 
and resistance exercise program [24]. Participants will be allowed to choose their modality (treadmill or 
recumbent stepper). At each session, modality, repetitions, heart rate, and rate of perceived exertion (RPE) 
will be recorded. Fidelity will be monitored by tracking the duration, intensity , and frequency of exercise. 
Additionally, for resistance training, weights and repetitions wil l be assessed.  
 The following criteria will be used to signal inadequate fidelity:  
 
1. Aerobic training:  
a) Does not complete duration     
b) Does not reach prescribed intensity  
c) Does not complete prescribed frequency (days per week)  
 2. Resistance t raining:  
a) Does not complete all exercises  
b) Does not complete prescribed number of repetitions  
c) Does not reach prescribed intensity (i.e., uses lower or higher resistance)  
d) Does not complete prescribed frequency (days per week)  
 
At each session, interventionists will verbally encourage subjects to reach exercise prescription goals. Failure to maintain frequency, duration, or intensity will be documented.  
 Quarterly review with the research team with be instituted to review intervention fidelity and deploy remedial strategies for interventionists.  
6 Study Procedures  and Schedule  
6.1 Schedule of Events  
See Attachment A ‘Schedule of Events’ . 
6.1.1  Standard of Care Study Procedures  
N/A 
6.2 Laboratory Procedures/Evaluations  
6.2.1  Clinical Laboratory Evaluations  
All subjects will undergo a 5- sample (10x4 mL of blood) oral glucose tolerance test (OGTT) at NYU CBI, 
where we carry out all evaluations involving intravenous (IV) catheters. We will ask subjects to abstain from taking oral medications such as metformin for 2 full days prior to all OGTT evaluations in order to obtain results that are unbiased by medication effects, which typically trigger insulin release from the pancreas or reduce glucose production in the liver. The rationale for doing the pre and post -intervention  
OGTT is to measure the degree of insulin resistance. Exercise has been shown to improve insulin 
sensitivity in patients with diabetes. We want to see if improvement in insulin sensitivity is correlated with 
MRI metrics . The OGTT has been used as a safe and standard procedure in our laboratory, and has 
been approved by our IRB for several years (s15- 00271). We will document all those medications and 
changes and if needed, will account for them statistically. Subjects will be asked to abstain from  taking 
their insulin on the morning of their visit. All diabetes medications will be brought to the visit so that they may be taken at the conclusion of the evaluation for which they need to be fasting for, and around the 
time they are given food prior to completion of the visit. Studies are performed in the morning after an 
overnight fast. Baseline bloods are obtained at time 0, prior to the consumption of the 75g glucose drink. 
We also obtain blood samples to measure inflammation that will help account for variable physiological 
Study number:  s18-00527   Page 15 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  conditions such as time of day and other risk factors. For the OGTT, samples are then collected at 30, 60, 
90, and 120 minutes post glucose ingestion. We will compute the Matsuda whole body Index of Insulin 
Sensitivity (ISI) as follows and will be used at the insulin resistance (IR) variable:  
 
 𝐼𝐼𝐼𝐼𝐼𝐼=  10,000
�[𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓  𝑓𝑓
𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑓𝑓𝑔𝑔 𝑥𝑥 𝑓𝑓
𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓  𝑓𝑓𝑓𝑓
𝑓𝑓𝑔𝑔𝑔𝑔𝑓𝑓𝑓𝑓 ] 𝑥𝑥 [𝑚𝑚
𝑔𝑔𝑓𝑓𝑓𝑓  𝑓𝑓𝑔𝑔𝑔𝑔
𝑔𝑔𝑔𝑔𝑓𝑓𝑔𝑔 𝑥𝑥 𝑚𝑚𝑔𝑔𝑓𝑓
𝑓𝑓 𝑓𝑓𝑓𝑓
𝑓𝑓𝑔𝑔𝑔𝑔𝑓𝑓𝑓𝑓  𝑑𝑑𝑔𝑔
𝑑𝑑𝑓𝑓
𝑓𝑓𝑓𝑓 𝑂𝑂𝑂𝑂
𝑂𝑂𝑂𝑂] 
  
Baseline bloods obtained at time 0 will also be analyzed for measuring HgbA1C  and C -reactive protein 
(CRP). In addition, we will use baseline bloods to estimate levels of hydrogen peroxide as a marker of ROS. None of these blood biomarkers will be used as an inclusion/exclusion criterion.  
6.3 Imaging Procedures  
All experiments will be performed on a 3T whole body scanner (Magnetom Prisma; Siemens Medical Solutions, Germany) available in the Department of Radiology at the NYU School of Medicine. We will 
use our recently developed dual- tuned (31P/1 H) coil array (C.1.6). The MRI scan will include 31P -MRI 
measurement of muscle oxidative capacity following a 90- second plantar flexion exercise at 40% MVC 
(Section C.1.1,2), dynamic post -contractile BOLD -measurements following brief 100% MVC every 90 s  
(Section C.1.3), IDEAL MRI for IMAT calculation, and DTI for assessment of peripheral nerve integrity (FA 
and ADC). The main MRI sequences and their acquisition parameters are summarized in Table 1.  
Additional sequences will include localizers and anatomical images for segmentation purposes.  
 
6.4 Study Schedule  
6.4.1  Baseline Visit  
6.4.1.1  Step 1: Consent 
The PI, Co- Investigator, Research Coordinator, or Research Data Associate will consent individuals at the 
Center for Biomedical Imaging. They will go over the consent form with the subject and answer any 
questions that may arise. When the subject has shown that he/she understands the process and has signed the form, he/she will be given a copy of the form and considered “enrolled” in the study.  
All subjects will ha ve the o ption to consent  remotely  (through send safe) instead of consenting in person. If 
the subject prefers to sign the consent form electronically, the research coordinator will be able to send the 
informed consent via email (send safe) to the subject. The research coordinator will go over the consent form with the subject and will give ample time to the subject to ask questions regarding the study,  
6.4.1.2  Step 2: Blood draw  
After the consent process is completed, participants will be required to have blood tests at t he CBI or at 
the outpatient lab located at TISCH hospital. At CBI a licensed nurse, radiology technician, or study team 
member with phlebotomy certification will place the IV line and at the outpatient lab at Tisch hospital a 

Study number:  s18-00527   Page 16 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  nurse will be performing the blood draw. A total of 14 tubes, approximately 59.2 mL of blood, will be 
collected. The following blood tests will be performed:  
• Insulin (fasted)  
• Glucose (fasted)  
• Complete Blood Count with Differential  
• Comprehensive Metabolic Panel  
• Lipid profile  
• Fibrinogen  
• Highly sensitive CRP  
• Thyroid Stimulating Hormone  
• Hemoglobin A1C  
• OGTT: subject will drink a sweet -tasting drink and then have his/her blood drawn (2 tubes) every 
30 minutes for a 2- hour duration.   
The following urine test will be performed:  
• Microalbumin  
 Note: The Center of Biomedical Imaging as well as other NYU Health Institutions are taking safety 
measure necessary to reduce the risk of subjects contacting COVID -19. As per NYU COVID -19 related 
policies, staff will ensure all rooms or MRI machines are disinfected prior to the subjects scan.  
6.4.1.3  Step 3:  MRI Session  
The MRIs will be performed on the day of consenting and blood tests, also at the CBI on the FDA -
approved 3T whole body scanner.  
 
All MRIs are reviewed by the licensed clinical radiologist on duty immediately as they are done. A report is 
issued and faxed to the PI the same day with the radiologist’s interpretation of the scan as well as 
recommendations based on any incidental findings. In the case of an incidental finding, either the PI or another investigator on the study will speak to the subject in person at their next visit or via phone regarding the new information. Types of incidental findings would be a bone infarct, meniscal tear, or 
meniscal destruction found on the MRI. A copy of the original image report will also be provided to the patient in person and they will be encouraged to follow up on the discovery with their treating physician. 
We will ask subjects to abstain for 2 full days prior to their MRI scan from taking oral diabetes medic ations 
such as metformin. Subjects will be asked to fast the night prior to visit. Subjects will be asked to not take 
their insulin on the morning of their visit. All diabetes medications will be brought to the visit so that they may be taken at the conclusion of the evaluation for which they need to be fasting for.  
6.4.2  Maximal Graded Exercise Testing (VO 2R Assessment)  
Maximal graded exercise testing  (VO 2R assessment)  will be performed prior to the 10- week exercise 
intervention by an exercise physiologist at Langone Orthopedic Center, 333 East 38th St. A standardized 
exercise protocol with a recumbent stepper/treadmill will be used (Trackmaster, USA ). We will  use a 
ramping protocol with increases in workload equivalent to 0.5 METS per 1 minute. Continuous moni toring 
of heart rate will be performed.  Additionally, blood pressure and RPE are measured at the end of each 
stage. Criteria for a “maximal” effort during exercise testing include: reaching a plateau in VO2 with increased workload, a respiratory exchange ratio of greater than or equal to 1.15, a peak HR within 85% of the age- predicted maximal HR  (in absence of beta blockage), and an RPE of greater than or equal to 18 
(ACSM Guidelines for Exercise Testing and Prescription 10
th edition, 2017. ) The test will be stopped before 
maximal effort was achieved if any of the following occur: angina, dyspnea, fatigue (voluntary exhaustion 
or inability to maintain a speed/cadency of 115 on the stepper), hypertension (250 mm Hg systolic or 115 
mm Hg diastolic), and hypot ension (>10mmHg drop in blood pressure with workload increase), or ischemic 
electrocardiographic abnormalities.  The same exercise physiologist will administer tests (before and after 
intervention). In addition to standardized protocols, the following procedures  will be used to minimize bias:  
1) The use of timed encouragement scripts  
2) No review of pre- intervention test  results before post  intervention tests  
 
Study number:  s18-00527   Page 17 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  6.4.3  Exercise Phase (10 weeks)  
All procedures related to exercise intervention and its safety have been previously published in the peer -
reviewed literature [15, 24, 60- 62]. Each participant will be prescribed an individualized,  10-week exercise 
program  (after the 4- week non- exercise phase)  with both aerobic and resistance  components, based on 
the ACSM  Guidelines  [15, 24] . Exercise training  will be performed under the supervision of a licensed 
physical therapist at the Department of Physical Therapy, 380 2nd Ave. Participants  will have the choice of 
using a treadmill or a recumbent stepper . The physical therapist will monitor blood glucose level, blood 
pressure, heart rate, and RPE during each exercise session.  
Additionally, in light of the COVID -19 pandemic, all subjects will be required to complete the PCR Covid 
test at a site that is convenient for them.  
 
Note: Due to COVID -19 one of the requirement policy for the Department of  Physical Therapy is to complete 
the PCR test within 5 days prior to patient’s  appointment. It is required that all subjects complete this testing 
as a way to reduce the risk of patients contacting COVID -19.  
 Aerobic Exercise:  The maximal workload obtained from  the VO2R assessment  will be used to calculate a 
moderate level of intensity (50– 70% of VO
2 reserve) for the aerobic training program. A brief overview of 
the program is provided in Table 2.  
 
Table 2  
Week  Day 1  Aerobic Exercise  Resistance Exercise  
 
1 1 30 mins, 50% VO 2R  Determine 1 RM max, 10 reps x 1 day,  
Record medication use, Utah Early Neuropathy 
Scale, Give Actigraph  
 2 30 mins, 50% VO 2R PROMIS Physical Function and Fatigue,  
Calf muscle performance  
 3 35 mins, 50% VO 2R 9 item Physical Performance Test  
2 1 35 mins, 50% VO 2R  Get Actigraph, 10 reps  
 2 35 mins, 50% VO 2R 15 reps  
 3 40 mins, 50% VO 2R  
3 1 40 mins, 50% VO 2R  15 reps  
 2 40 mins, 50% VO 2R 15 reps  
 3 45 mins, 50% VO 2R  
4 1 45 mins, 50% VO 2R  15 reps  
 2 45 mins, 50% VO 2R 15 reps  
 3 45 mins, 50% VO 2R  
5 1 45 mins, 60% VO 2R  15 reps  
 2 45 mins, 60% VO 2R 15 reps  
 3 45 mins, 60% VO 2R  
6 1 45 mins, 70% VO 2R 15 reps  
 2 45 mins, 70% VO 2R 15 reps  
 3 45 mins, 70% VO 2R  
7 1 50 mins, 70% VO 2R 20 reps  
 2 50 mins, 70% VO 2R 20 reps  
 3 50 mins, 70% VO 2R  
8 1 50 mins, 70% VO 2R 20 reps  
 2 50 mins, 70% VO 2R 20 reps  
 3 50 mins, 70% VO 2R  
9 1 50 mins, 70% VO 2R 20 reps  
 2 50 mins, 70% VO 2R 20 reps  
Study number:  s18-00527   Page 18 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017   3 50 mins, 70% VO 2R Give Actigraph  
10 1 50 mins, 70% VO 2R  20 reps  
 2 50 mins, 70% VO 2R PROMIS Physical Function and Fatigue,  
Calf muscle performance  
 3 50 mins, 70% VO 2R 9 item Physical Performance Tests,  
Get Actigraph  
 
 
Resistance Training:  will include the following exercises: biceps /triceps curls,  seated row, squats, and 
heel raises. Dumbbells will be used for strength training, with resistance levels gradually increased to maintain RPE in a moderate range (7–8 out of 10)  for each participant. The weight of the dumbbells will be 
based on RPE 5- 7, on a scale of 0- 10, and 50- 70% of 1 repetition maximum weight. There will be 1 to 5 
minutes of rest between each exercise. We will use the following sequence of exercises in this study: Blood 
pressure, blood sugar check, warm -up, aerobic exercise, resistance exercise, and stretch.  
 
Prior to each exercise session, the following will be assessed, consistent with guidelines set forth by the 
A
merican Physical Therapy Association and American Diabetes Association.   
• Foot: a visual inspection for cuts , blisters , cracked skin, and/or ulcer development  
• Finger stick blood glucose:  
o If hypoglycemic (less than 100 mg/dL), carbohydrate snacks will be provided, and glucose 
testing will be r epeated in 15- 20 min.  
o If hyperglycemic (more than 300 mg/dL) and the participant was not taking insulin, exercise 
will be permitted with close monitoring of blood glucose every 10 to 15 minutes to ensure 
that the blood glucose level does  not increase with activity.  
o If hyperglycemic (more than 300 mg/dL) and the participant was taking insulin, urine will 
be checked for ketosis. If the ketone test result is  positive, then exercise will be postponed. 
If the ketone test result was negative,  then exercise will be  permitted with close monitoring 
of blood glucose every 10 to 15 minutes.  
• Blood pressure: participant s will not be permitted to exercise if blood pressure is higher than 
200/110 mm Hg  
• RPE will be assessed at baseline and every 20 minutes. A moderate RPE level (11– 13 on the 17-
point scale)  should be achieved at each session.  
 
Adverse event tracking:  A dverse events will be tracked at each session. Events will be classified as related 
to exercise intervention or unrelated to exercise intervention. Severity will be classified using the Common 
Terminology Criteria for Adverse Events (CTCAE) v5.0. Aaron Chidakel, M.D. will serve as the safety 
monitor for this study  and review adverse events as necessary.  
6.4.4  Post -Exercise Phase Visit  
Participants will undergo blood tests, VO 2R, and a final MRI to compare with results collected prior to the 
exercise intervention. The final visit should occur within two weeks after the last exercise session. This will allow for feasible scheduling, data collection, and study completion considerations . 
6.4.5  Withdrawal Visit  
Participants will be invited to complete endpoint testing even if they choose to withdraw from the 
intervention.  Endpoint testing will include:  
• BMI 
• HbA1c  and C -reactive protein  
• MNSI symptom questionnaire and the PROMIS physical function and fatigue questionnaire  
• MNSI physical exam  
• VPT and Calf Muscle performance  
• Plasma levels of hydrogen peroxide  
• Lower leg muscle performance & physical activity  
Study number:  s18-00527   Page 19 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  • MRI 
6.5 Concomitant Medications, Treatments, and Procedures  
All concomitant prescription medications, over -the-counter medications, and non- prescription medications 
taken during study participation will be recorded on the CRF. For this protocol, a prescription medication 
is defined as a medication that can be prescribed only by a properly authorized/licensed clinician.  
6.5.1  Precautionary Medications, Treatments, and Procedures  
N/A 
6.6 Prohibited Medications, Treatments, and Procedures  
Oral medications such as Metformin are prohibited two full days prior to all OGTT evaluations. Participants will be asked not to take their insulin on the morning of their visit at CBI.  
6.7 Prophylactic Medicat ions, Treatments, and Procedures  
• If hypoglycemic (less than 100 mg/dL), carbohydrate snacks will be provided and glucose testing 
will be repeated in 15- 20 min 
• No other prophylactic medications will be provided by study personnel  
6.8 Participant Access to Study Intervention at Study Closure  
Participants will be encouraged to continue exercising upon completion of the intervention as this will be beneficial to their health.  
7 Assessment of Safety  
7.1 Specification of Safety Parameters  
7.1.1  Definition of Adverse Events (AE)  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of the study.  Inter-current illnesses or injuries should be regarded as adverse events.  
Abnormal results of diagnostic procedures are considered to be AEs  if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests 
• is considered by the investigator to be of clinical significance 
7.1.2  Definition of Serious Adverse Events (SAE)  
Serious Adverse Event  
Adverse events are classified as serious or non- serious.  A serious adverse event  (SAE) is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospital st ay 
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may jeopardize the subject  and may require intervention to prevent one of the 
other serious outcomes noted above.  For example, drug overdose or abuse, a seizure that did not result 
Study number:  s18-00527   Page 20 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  in in-patient hospitalization, or intensive treatment of bronchospasm in an emergency department would 
typically be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non- serious 
adverse events .  
7.1.3  Definition of Unanticipated Problems (UP)  
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all  of  the following criteria:  
• Unexpected in nature, severity, or frequency  (i.e. not described in study -related documents such 
as the IRB -approved protocol or consent form, the investigators brochure, etc .) 
• Related or possibly related to participation in the research ( i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by the 
procedures involved in the research)  
• Suggests that the research places subjects or others at greater risk of harm  ( includin g physical, 
psychological, economic, or social harm).  
7.2 Classification of an Adverse Event  
7.2.1  Severity of Event  
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe  – Event s interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life- threatening or incapacitating.  
7.2.2  Relationship to Study Intervention  
The clinician’s assessment of an AE's relationship to study intervention is part of the documentation process, but it is not a factor in determining what is or is not reported in the study. If there is any doubt as 
to whether a clinical observation is an AE, the event should be reported. All AEs  must have their 
relationship to study intervention assessed. In a clinical trial, the study intervention must always be 
suspect. To help assess, the following guidelines are used.  
 
• Related – The AE is known to occur with the study intervention, there is a reasonable possibility 
that the study intervention caused the AE, or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been est ablished.  
7.2.3  Expectedness 
Aaron Chidakel, MD, the study’s safety officer, will be responsible for determining whether an AE is expected or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study intervention.  
 
Adverse events will be collected at each study visit by the technologist performing the MRI scan.  
Study number:  s18-00527   Page 21 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  7.3 Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care. All AEs including local and systemic 
reactions not meeting the criteria for SAEs will be captured on the appropriate CRF. Information to be 
collected includes event description, date of onset, clinician’s assessment of severity, relationship to study intervention (assessed only by those with the training and authority to make a diagnosis), and date of resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout the study.  
 Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of 
onset and duration of each episode.  
 The PI/research coordinator  will record all reportable events with start dates occurring any time after 
informed consent is obtained until 7 (for non- serious AEs) or 30 days (for SAEs) after the last day of study 
participation. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit.   All unresolved adverse events should be followed by the investigator until the events are resolved, the subject is lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled vi sit, the 
investigator should instruct each subject to report any subsequent event(s) that the subject, or the 
subject’s personal physician, believes might reasonably be related to participation in this study.  The 
investigator should notify the study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that may reasonably be related to this study.  
7.4 Reporting Procedures – Notifying the IRB  
7.4.1  Adverse Event Reporting 
Severe AEs will be reported to the IRB within 5 working days. Other adverse events will not be reported to the IRB.  
7.4.2  Unanticipated Problem Reporting  
Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report form. It is the site investigator’s responsibility to report UPs to their IRB and to the NIH. The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be reported to the IRB and to the NIH within 24 hours of the investigator becoming aware of the event . 
• Any other UP will be reported to the IRB and to the NIH within 5 working days of the investigator becoming aware of the problem.  
Study number:  s18-00527   Page 22 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  • All UPs should be reported to appropriate institutional officials (as required by an institution’s 
written reporting procedures), the supporting agency head (or designee), and OHRP within 5 working days of the IR’s receipt of the report of the problem from the investigator.  
7.4.3  Reporting of Pregnancy 
Should a participant get pregnant during the course of the study, he/she will be discontinued immediately. The pregnancy will be documented and reported to the IRB.  
7.5 Safety Oversight  
Safety oversight will be under the direction of the safety officer, Dr. Aaron Chidakel. Dr. Chidakel’s study responsibilities include the following:   
1) Review all AEs/SAEs on a regular basis throughout the trial  
2) Be available to advise the investigators on trial- related medical questions or problems  
3) Evaluate cumulative participant safety data and make recommendations regarding the safe 
continuation of the study.  
8 Data Safety Monitoring Plan  
Meetings among members of the research team will be held quarterly to discuss the preliminary report and to ensure that the study is being conducted according to the protocol. Additionally, members will discuss whether any protocol amendments are necessary and whether the safety/privacy of subjects who are participating is being respected. The following events/data points will be reviewed:  
• Subject attrition  
• Occurrence of adverse events  
• Subject compliance  
• Subject complaints  
• Site issues (i.e. scheduling, recruiting, staffing, study flow, etc.)  
There are no predefined stopping rules for the entire study.  
 
Responsibilities and roles for gathering, evaluating and monitoring the data:  
• PI will gather data regarding recruitment rate. This will be reviewed with members of the research 
team every month.  
• PI and co- investigators overseeing the MRI scan will gather data regarding unanticipated adverse 
events. The PI and co- investigators will report any serious adverse event immediately to the NYU 
IRB. 
 Information about the monitoring entity:  
• The Individual Data Monitor will be the PI, Ryan Brown, NYU Langone Health, Department of 
Radiology, 660 First Avenue, 4
th floor, New York NY 10016, 212- 263- 3396. The PI will follow the 
policies and procedures of the IRB for monitoring this study for safety concerns, with ongoing updates from the co- investigators on a continuous basis.  
 
Assessments:  
• The PI and Co- PI will assess the risk to benefit ratio and determine whether the level of risk and 
patient safety were accurately outlined and accounted for in study application, protocol and consent. These meetings will occur annually when the study is being prepared for re- approval.  The 
IRB will be informed if any reasons warrant “holding” the study.  
 
Procedures for Communicating – D issemination of safety information  
As appropriate:  
• The PI will notify in writing the outcomes of the monitoring events. Any significant deviation will be reported immediately to the IRB using the IRB Reportable New Information form of Research Navigator.  
Study number:  s18-00527   Page 23 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  • New information that would affect the safety of the subject or his/her decision to participate in the 
study will be provided by the PI or his co- investigators.  
9 Statistical Considerations  
9.1 Statistical and Analytical Plans  
The primary objective is to assess and compare the interventions (exercise versus control phase in the same individual) in terms of the baseline to follow -up change in the following outcomes: 1) DTI, plasma 
ROS level, and the MNSI assessment of DPN symptoms (Aim 1); and 2) leg mitochondrial function, oxidative capacity (31P -MRI), peak MV response (BOLD -MRI), the proportion of fat -free muscle (IDEAL-
MRI) and leg muscle strength (Aim 2).  
9.2 Statistical Hypotheses 
 Hypothesis 1a: Exercise will improve peripheral nerve integrity (DTI fractional anisotropy will increase, 
and the apparent diffusion coefficient will decrease).  
Hypothesis 1b : Exercise will decrease plasma ROS levels.  
Hypothesis  1c: Exercise will improve DPN symptoms, assessed with the MNSI.  
Hypothesis 2a: Exercise will increase leg mitochondrial function, as defined by an increase in oxidative 
capacity  (measured using  
31P-MRI).  
Hypothesis 2b: Exercise will improve leg MV function, as defined by an increase in peak MV response  
(measur ed using BOLD -MRI).  
Hypothesis 2c: E xercise will decrease intramuscular fat and increase levels of fat -free muscle 
(measured using IDEAL -MRI) . 
9.3 Description of Statistical Methods  
A weighted paired sample t -test will be used to assess whether each outcome changed from baseline to 
follow -up as a result of the exercise intervention. Weighted analysis of covariance (ANCOVA) will be used 
to compare the time points  in terms of the change in each outcome. The change in each outcome from 
baseline to follow -up will be the dependent variable and the ANCOVA model will include the matching 
factors (age, baseline MNSI) and the measure of general activity level as numeric covariates and the binary 
indicator of intervention as a classification factor. The secondary objective is to assess the extent to which 
exercise induced improvements in DTI outcomes are mediated or explained by reduction in ROS. After 
testing the effect of the intervention on the change in DTI and the correlation between changes in DTI and ROS, an incomplete causal pathway meditational analysis will be conducted using the method of Baron and Kenny [63] with a bootstrap based test of the indirect (mediation) effect of ROS. The exploratory 
objective to identify baseline factors (e.g., age, MNSI, general activity) predictive of improvement, 
represented as the baseline to follow -up change in each outcome, will be addressed using linear regression 
and bivariate correlations. This analysis will be stratified by intervention and then conducted using data 
from both intervention groups combined. In each case, the assessment of compliance will be included as a 
weighting factor.  
 
9.3.1  General Approach  
In this longitudinal , single -center study we will recruit 40 T2DM patients. Each participant will be imaged 
two times : upon  enrollment (visit 1) and after completion of the 10 week exercise program (visit 3).  
9.3.2  Analysis of the Primary Efficacy Endpoint(s)  
 
A matched -pairs Wilcoxon signed rank test will be applied to the within -subject change in each 
outcome among subjects demonstrating full compliance with the exercise program. Additionally, weighted analysis of covarianc e (ANCOVA) will be used to test  the change  in each outcome adjusting 
for the measured level of compliance using data from all subjects.  The values of  each outcome  at 
Study number:  s18-00527   Page 24 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  baseline and follow -up for all subjects will be the  dependent  variable and the ANCOVA  model  will 
include  time (baseline versus follow -up) as the within- subject factor of interest covariates, the measure  
of com pliance as numeric covariate and an anonymized subject ID as a classification factor so that 
the comparison of times will be based on  their within -subject difference. The secondary objective is to 
assess the extent to which exercise induced improvements in DTI outcomes are can be at least 
partially explained by reduction in ROS will be addressed using linear regression, The baseline to follow -up change in each outcome will be the dependent variable and the model will include the 
measure of compliance as a numeric factor and the within- subject change in ROS as the numeric 
factor of interest. A second regression will be conducted with base line factors (e.g., age, MNSI,
 general 
activity) added to the model in order to identify factors predictive of improvement in each outcome.  
 
9.3.3  Analysis of the Secondary Endpoint(s)  
NA 
9.3.4  Adherence and Retention Analyses  
The analysis will follow the intention- to-treat (ITT) principle and include data from every subject 
irrespective of whether the subject was compliant with the assigned intervention. A quantitative assessment of compliance with the intervention, ranging from 0 (complete non- compliance) to 1 (full 
compliance), will be included as a weighting factor to allow more compliant subjects to contribute more to the analysis. The weight for the control phase will be set to 1 since subjects are not required to exercise.  
 
9.3.5  Baseline Descriptive Statistics  
In thi s longitudinal  study, each participant will participate in both an exercise phase. Therefore, there will 
be no comparison between groups.  
9.3.6  Exploratory Analyses  
The exploratory objective to identify baseline factors (e.g., age, MNSI, general activity) predictive of 
improvement, represented as the baseline to follow -up change in each outcome, will be addressed using 
linear regression and bivariate correlations. This analysis will be stratified by intervention and then 
conducted using data from both phases  combined. In each case, the assessment of compliance will be 
included as a weighting factor  
9.4 Sample Size  
Assessment of statistical power was based on tests conducted at the two- sided 5% significance level and 
the preliminary data in Table 3. Under the conservative assumption of a moderate within- subject correlation 
(ρ=0.5) between baseline and follow -up measures, the expected mean and SD of the within- subject change 
in the outcomes is given in Table 4. It is noted that statistical power will be higher if ρ>0.5 as observed in the majority of 
longitudinal imaging studies. With data from 40 subjects included in t he 
analysis according to the ITT principal the study will have 80% power to detect a mean within- subject change in each 
outcome among subjects in each intervention 
group provided the change is between 10% and 
18% when expressed as a percentage of the mean at baseline. The mean percentage change 
observed in the preliminary data among subjects 

Study number:  s18-00527   Page 25 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  in the exercise group ranged from 23% to 34% across outcomes, implying that the study will have >80% 
power to detect anticipated changes resulting from exercise. The minimum difference in terms of the mean 
within -subject change in a given outcome that is detectable with 80% power is 4.5% for BOLD response 
and 120% for PCr resynthesis where each difference is expressed as a percentage of the mean within-
subject change. The difference in terms of the mean within subject change observed in the preliminary data was 5.2% for BOLD response and 176% for PCr resynthesis, respectively. Since the observed differences exceed the minimum detectable differences, the study will have >80% power to detect anticipated group differences.   
 
10 Source Documents and Access to Source Data/Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source documents.  Examples of these original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, subject files, and records kept at the pharmacy, at the laboratories, and at 
medico- technical departments involved in the clinical trial.   
 
The study CRF is the primary data collection instrument for the study.  All data requested on the CRF must be recorded.  All missing data must be explained.  If a space on the CRF is left blank because the 
procedure was not done or the question was not asked, write “N/D”.  If the item is not applicable to the 
individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any entry error has been made, to correct such an error, draw a single straight line through the incorrect entry and enter the correct data above it.  All such changes must be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For clarif ication of illegible or uncertain entries, print the clarification above the item, then initial 
and date it.  
 Access to study records will be limited to IRB -approved members of the study team. The investigator will 
permit study -related monitoring, audits, and inspections by the IRB/EC , the sponsor, government 
regulatory bodies, and University compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.).  
 Participation as an investigator in this study implies acceptance of potential inspection by government regulatory authorities and applicable University compliance and quality assurance offices.  
 
11 Ethics/Protection of Human Subjects  
11.1 Ethical Standard  
The investigator will ensure that this study is conducted in full conformity with Regulations for the 
Protection of Human Subjects of Research codified in 45 CFR Part 46.  
11.2 Institutional Review Board  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study. All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants 
need to be re- consented.  
Study number:  s18-00527   Page 26 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  11.3 Informed Consent Process  
11.3.1  Consent/Assent and Other Informational Documents Provided to Participants  
Consent forms describing in detail the study intervention, study procedures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting intervention.  
 
11.3.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families. Consent forms will be IRB -
approved and the participant will be asked to read and review the document. The investigator will explain 
the research study to the participant and answer any questions that may arise. All participants will receive 
a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their surrogates or think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically 
for the study. The participants may withdraw consent at any time throughout the course of the trial. A 
copy of the signed  informed consent document will be given to the participants for their records. The 
rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.  
 
A copy of the signed informed consent document will be stored in the subject’s research record. The 
consent process, including the name of the individual obtaining consent, will be thoroughly documented in the subject’s research record. Any alteration to the standard consent process (e.g. use of a translator, consent from a legally authorized representative, consent document presented orally, etc.) and the justification for such alteration will likewise be documented.  
11.4 Participant and Data Confidentiality  
Information about study subjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a 
signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have acc ess to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, 
retains the ability to use all information collected prior to the revocation of subject authorization.  For 
subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
 All the MRI data will be archived into the research image database in the Department of Radiology at the 
New York University Medical Center. Dr. Brown (PI) will monitor all the MRI data and save the data on the 
NYU Radiology password- protected server. A copy of the data will be kept on the P.I.’s workstation, 
which has a secure password protection. Every attempt will be made by Dr. Brown to maintain all 
information collected in this study strictly confidential, except as may be required by court order or by law. 
All clinical and exercise -related data will be de- identified and stored at the Arthur J. Nelson Jr. Human 
Performance Lab at the Department of Physical Therapy. All digital materials will be stored on a secure 
password protected server with access given only to authorized study personnel. All paper documents will 
be stored for three years in a locked file cabinet and lab, with access given only to authorized study personnel. Dr. Rao will work with the Data Services and Data Management Planning Team 
Study number:  s18-00527   Page 27 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  (http://guides.nyu.edu/data_management) to develop and implement this plan. Authorized representatives 
of the New York University Institutional Review Board (IRB), a committee charged with protecting the 
rights and welfare of research subjects, may be provided access to medical or research records that 
identify subjects by name. In any publication or presentation resulting from this research, the subjects will not be identified by name. Any serious adverse effects to the participants will be immediately communicated to the IRB as well as our departmental research committee that oversees clinical research  
11.5 Data Collection and Management Responsibilities  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the 
data reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of 
data. Black ink is required to ensure clarity of reproduced copies. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ER ASE, 
OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 
11.6 Study Records Retention  
Study documents will be retained for the longer of 3 years after close out or 5 years after final reporting/publication. These documents should be retained for a longer period, however, if required by local regulations. No records will be destroyed without the written consent of the NIH, if applicable. It is the responsibility of the NIH to inform the investigator when these documents no longer need to be 
retained.  
11.7 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol or GCP requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the site and implemented promptly.  
 It is the responsibility of the site to use continuous vigilance to identify and report deviations within 5 
working days of identification of the protocol deviation. Protocol deviations must be reported to the local 
IRB per their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  
12 Study Finances  
12.1 Funding Source  
This study is financed through a grant R01DK114428 from the National Institute of Diabetes and Kidney Disease (NIDDK)  
12.2 Costs to the Participant  
There will be no cost to the participant for enrolling in this study.  
12.3 Participant  Reimbursements or Payments  
Each participant will be offered $500 upon completion of the 10- week supervised exercise intervention. 
They will also receive a clincard (similar to a debit/credit card) of $50 for undergoing each MRI scan (t wo 
in total) and up to $20 reimbursement for travel to our facilities.  
 If attendance during the exercise phase drops below 80% , reimbursement will be prorated based on the 
number of sessions completed. Participants will receive $17 per session.  
Study number:  s18-00527   Page 28 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  13 Conflict of Interest  Policy  
Any investigator who has a conflict of interest with this study (patent ownership, royalties, or financial ga in 
greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by the NYU 
Langone Conflict of Interest Committee with a Committee- sanctioned conflict management plan that has 
been reviewed and approved by the study sponsor prior to participation in this study.  All NYULMC  
investigators will follow the applicable  conflict of interest policies . 
14 References  
[1] (2011, August 27 2014). National diabetes statistics, 2011. NIH Publication No: 11- 3892 National 
Diabetes Information Clearinghouse.  
[2] G. E. Reiber, R. E. Pecoraro, and T. D. Koepsell, "Risk factors for amputation in patients with 
diabetes mellitus. A case- control study," Annals of internal medicine, vol. 117, pp. 97- 105, 1992.  
[3] B. A. Lipsky, J. A . Weigelt, X. Sun, R. S. Johannes, K. G. Derby, and Y. P. Tabak, "Developing and 
validating a risk score for lower -extremity amputation in patients hospitalized for a diabetic foot 
infection," Diabetes Care, vol. 34, pp. 1695- 1700, 2011.  
[4] S. Tesfaye and D. Selvarajah, "Advances in the epidemiology, pathogenesis and management of 
diabetic peripheral neuropathy," Diabetes/metabolism research and reviews, vol. 28, pp. 8- 14, 
2012.  
[5] S. Tesfaye, A. J. Boulton, and A. H. Dickenson, "Mechanisms and management  of diabetic painful 
distal symmetrical polyneuropathy," Diabetes care, vol. 36, pp. 2456- 2465, 2013.  
[6] A. J. Boulton, A. I. Vinik, J. C. Arezzo, V. Bril, E. L. Feldman, R. Freeman, et al. , "Diabetic 
neuropathies a statement by the American Diabetes Association," Diabetes care, vol. 28, pp. 956 -
962, 2005.  
[7] M. D. Allen, B. Major, K. Kimpinski, T. J. Doherty, and C. L. Rice, "Skeletal muscle morphology and 
contractile function in relation to muscle denervation in diabetic neuropathy," Journal of Applied 
Physiology, vol. 116, pp. 545- 552, 2014.  
[8] T. N. Hilton, L. J. Tuttle, K. L. Bohnert, M. J. Mueller, and D. R. Sinacore, "Excessive adipose tissue 
infiltration in skeletal muscle in individuals with obesity, diabetes mellitus, and peripheral 
neuropathy: association with performance and function," Physical therapy, vol. 88, pp. 1336- 1344, 
2008.  
[9] H. Andersen, E. Stålberg, M. D. Gjerstad, and J. Jakobsen, "Association of muscle strength and electrophysiological measures of reinnervation in diabetic neuropathy," Muscle & nerve, vol. 21, 
pp. 1647- 1654, 1998.  
[10] H. Andersen, P. Gadeberg, B. Brock, and J. Jakobsen, "Muscular atrophy in diabetic neuropathy: a stereological magnetic resonance imaging study," Diabetologia, vol. 40, pp. 1062- 1069, 1997.  
[11] C. S. Andreassen, J. Jakobsen, and H. Andersen, "Muscle weakness a progressive late 
complication in diabetic distal symmetric polyneuropathy," Diabetes, vol. 55, pp. 806- 812, 2006.  
[12] H. Andersen, "Muscular endurance in long- term IDDM patients," Diabetes Care, vol. 21, pp. 604 -
609, 1998.  
[13] C. G. Horlings, B. G. Van Engelen, J. H. Allum, and B. R. Bloem, "A weak balance: the contribution 
of muscle weakness to postural instability and falls," Nature Clinical Practice Neurology, vol. 4, pp. 
504-515, 2008.  
[14] A. V. Schwartz, E. Vittinghoff, D. E. Sellmeyer, K. R. Feingold, N. De Rekeneire, E. S. Strotmeyer , 
et al. , "Diabetes -related complications, glycemic control, and falls in older adults," Diabetes Care, 
vol. 31, pp. 391 -396, 2008.  
[15] A. Schwartz, "Diabetes mellitus: does it affect bone?,"  Calcified tissue international, vol. 73, pp. 
515-519, 2003.  
[16] R. E. Pecoraro, G. E. Reiber, and E. M. Burgess, "Pathways to diabetic limb amputation: basis for prevention," Diabetes Care, vol. 13, pp. 513 -521, 1990.  
[17] J. Apelqvist, J. Larsson, and C. D. Agardh, "Long- term prognosis for diabetic patients with foot 
ulcers," Journal of internal medicine, vol. 233, pp. 485 -491, 1993.  
[18] M. Tavakoli, I. N. Petropoulos, and R. A. Malik, "Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot," Journal of diabetes science and technology, vol. 7, pp. 1179- 1189, 
2013.  
Study number:  s18-00527   Page 29 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  [19] A. J. Boulton, P. Kempler, A. Ametov, and D. Ziegler, "Whither pathogenetic treatments for diabetic 
polyneuropathy?," Diabetes/metabolism research and reviews, vol. 29, pp. 327- 333, 2013.  
[20] R. S. Taylor, A. Brown, S. Ebrahim, J. Jolliffe, H. Noorani, K. Rees , et al., "Exercise -based 
rehabilitation for patients with coronary heart disease: systematic review and meta- analysis of 
randomized controlled trials," The American journal of medicine, vol. 116, pp. 682 -692, 2004.  
[21] R. J. Sigal, G. P. Kenny, N. G. Boulé, G. A. Wells, D. Prud'homme, M. Fortier , et al. , "Effects of 
aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomi zed 
trial," Annals of internal medicine, vol. 147, pp. 357- 369, 2007.  
[22] S. R. Colberg, R. J. Sigal, B. Fernhall, J. G. Regensteiner, B. J. Blissmer, R. R. Rubin , et al. , 
"Exercise and type 2 diabetes: the American College of Sports Medicine and the Amer ican 
Diabetes Association: joint position statement," Diabetes Care, vol. 33, pp. e147- 67, Dec 2010.  
[23] P. M. Kluding, M. Pasnoor, R. Singh, L. J. D'Silva, M. Yoo, S. A. Billinger , et al., "Safety of Aerobic 
Exercise in People With Diabetic Peripheral Ne uropathy: Single- Group Clinical Trial," Physical 
therapy, vol. 95, pp. 223 -234, 2015.  
[24] P. M. Kluding, M. Pasnoor, R. Singh, S. Jernigan, K. Farmer, J. Rucker , et al. , "The effect of 
exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy," Journal of Diabetes and its Complications, vol. 26, pp. 424- 429, 
2012.  
[25] S. A. Billinger, J.- F. V. Sisante, A. S. Alqahtani, M. Pasnoor, and P. M. Kluding, "Aerobic Exercise 
Improves Measures of Vascular Health in Diabetic Peripheral Neuropathy," International Journal of 
Neuroscience, vol. 127, pp. 80- 85, 2016.  
[26] S. Dixit, A. G. Maiya, and B. Shastry, "Effect of aerobic exercise on peripheral nerve functions of 
population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, parallel group 
randomized controlled trial," Journal of diabetes and its complications, vol. 28, pp. 332 -339, 2014.  
[27] H. C. Gerstein, M. E. Miller, R. P. Byington, D. C. Goff, Jr., J. T. Bigger, J. B. Buse , et al. , "Effects 
of intensive glucose lowering in type 2 diabetes," New England Journal of Medicine, vol. 358, pp. 
2545- 2559, Jun 12 2008.  
[28] A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, et al. , "Intensive blood 
glucose control and vascular outcomes in patients with type 2 diabetes," New England Journal of 
Medicine, vol. 358, pp. 2560- 2572, Jun 12 2008.  
[29] T. Moritz, W. Duckworth, and C. Abraira, "Glucose control and vascular complications in veterans 
with type 2 diabetes (vol 36 0, pg 129, 2009)," New England Journal of Medicine, vol. 361, pp. 1024-
1025, Sep 3 2009.  
[30] R. A. Malik, "Which test for diagnosing early human diabetic neuropathy?," Diabetes, vol. 63, pp. 
2206- 2208, 2014.  
[31] F. Tecilazich, T. Dinh, T. E. Lyons, J. Gu est, R. A. Villafuerte, C. Sampanis , et al., "Postexercise 
phosphocreatine recovery, an index of mitochondrial oxidative phosphorylation, is reduced in diabetic patients with lower extremity complications," Journal of vascular surgery, vol. 57, pp. 997-
1005, 2013.  
[32] T. Dinh, J. Doupis, T. E. Lyons, S. Kuchibhotla, W. Julliard, C. Gnardellis , et al., "Foot muscle 
energy reserves in diabetic patients without and with clinical peripheral neuropathy," Diabetes 
Care, vol. 32, pp. 1521- 1524, 2009.  
[33] R. L. G reenman, L. Khaodhiar, C. Lima, T. Dinh, J. M. Giurini, and A. Veves, "Foot small muscle 
atrophy is present before the detection of clinical neuropathy," Diabetes Care, vol. 28, pp. 1425-
1430, Jun 2005.  
[34] P. Parasoglou, D. Xia, G. Chang, A. Convit, and R. R. Regatte, "Three- dimensional mapping of the 
creatine kinase enzyme reaction rate in muscles of the lower leg," NMR Biomed, vol. 26, pp. 1142-
1151, 2013.  
[35] P. Parasoglou, L. Feng, D. Xia, R. Otazo, and R. R. Regatte, "Rapid 3D -Imaging of 
Phosphocreatine Recovery Kinetics in the Human Lower Leg Muscles with Compressed Sensing," 
Magnetic Resonance in Medicine, vol. 68, pp. 1738 –1746, 2012.  
[36] J. M. Slade, T. F. Towse, V. V. Gossain, and R. A. Meyer, "Peripheral microvascular response to muscle contraction is unaltered by early diabetes but decreases with age," Journal of Applied 
Physiology, vol. 111, pp. 1361- 1371, 2011.  
Study number:  s18-00527   Page 30 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  [37] R. A. Meyer, T. F. Towse, R. W. Reid, R. C. Jayaraman, R. W. Wiseman, and K. K. McCully, "BOLD 
MRI mapping of transient hyperemia in skeletal muscle after single contractions," NMR in 
biomedicine, vol. 17, pp. 392 -398, 2004.  
[38] T. F. Towse, J. M. Slade, and R. A. Meyer, "Effect of physical activity on MRI -measured blood 
oxygen level -dependent transients in skeletal muscle after brief contractions," J Appl Physiol 
(1985), vol. 99, pp. 715 -22, Aug 2005.  
[39] J. M. Slade, D. Hurley, B. Riedinger, J. Cross, E. Williams, G. S. Abela, et al., "Aerobic exercise 
improves microvacular function in older adults," in American College of Sports Medicine Annual 
Meeting , Boston, MA, 2016, p. 1031.  
[40] C. Wu, G. Wang, Y. Zhao, W. Hao, L. Zhao, X. Zhang , et al. , "Assessment of tibial and common 
peroneal nerves in diabetic peripheral neuropathy by diffusion tensor imaging: a case control 
study," European Radiology, pp. 1- 9, 2016.  
[41] M. O. Breckwoldt, C. Stock, A. Xia, A. Heckel, M. Bendszus, M. Pham , et al. , "Diffusion tensor 
imaging adds diagnostic accuracy in magnetic resonance neurography," Investigative radiology, 
vol. 50, pp. 498 -504, 2015.  
[42] T. Takagi, M. Nakamura, M. Yamada, K. Hikishima, S. Momoshima, K. Fujiyoshi , et al. , 
"Visualization of peripheral nerve degeneration and regeneration: monitoring with diffusion tensor tractography," Neuroimage, vol. 44, pp. 884 -892, 2009.  
[43] H. C. Lehmann, J. Zhang, S. Mori, and K. A. Sheikh, "Diffusion tensor imaging to assess axonal regeneration in peripheral nerves," Experimental neurology, vol. 223, pp. 238- 244, 2010.  
[44] K. A. Sheikh, "Non -invasive imaging of nerve regeneration," Experimental neurology, vol. 223, pp. 
72-76, 2010.  
[45] S. Kamath, N. Venkatanarasimha, M. Walsh, and P. Hughes, "MRI appearance of muscle denervation," Skeletal radiology, vol. 37, pp. 397 -404, 2008.  
[46] M. Vaeggemose, M. Pham, S. Ringgaard, H. Tankisi, N. Ejskjaer, S. Heiland, et al., "Magnetic 
Resonance Neurography Visualizes Abnormalities in Sciatic and Tibial Nerves in Patients with 
Type 1 Diabetes and Neuropathy," Diabetes, p. db161049, 2017.  
[47] D. C. Karampinos, T. Baum, L. Nardo, H. Alizai, H. Yu, J. Carballi do‐Gamio , et al. , 
"Characterization of the regional distribution of skeletal muscle adipose tissue in type 2 diabetes 
using chemical shift ‐based water/fat separation," Journal of Magnetic Resonance Imaging, vol. 35, 
pp. 899- 907, 2012.  
[48] J. Tsao and Y. Jiang, "Hierarchical IDEAL: Fast, robust, and multiresolution separation of multiple 
chemical species from multiple echo times," Magnetic Resonance in Medicine, vol. 70, pp. 155-
150, 2012.  
[49] M. T. Durheim, C. A. Slentz, L. A. Bateman, S. K. Mabe, and W. E. Kraus, "Relationships between exercise -induced reductions in thigh intermuscular adipose tissue, changes in lipoprotein particle 
size, and visceral adiposity," American Journal of Physiology -Endocrinology and Metabolism, vol. 
295, pp. E407- E412, 2008.  
[50] M. C. Mojtahedi, M. P. Thorpe, D. C. Karampinos, C. L. Johnson, D. K. Layman, J. G. Georgiadis , 
et al. , "The effects of a higher protein intake during energy restriction on changes in body 
composition and physical function in older women," The Journals  of Gerontology Series A: 
Biological Sciences and Medical Sciences, p. glr120, 2011.  
[51] G. F. Fletcher, G. J. Balady, E. A. Amsterdam, B. Chaitman, R. Eckel, J. Fleg , et al. , "Exercise 
standards for testing and training: a statement for healthcare professionals from the American Heart Association," Circulation, vol. 104, pp. 1694- 1740, 2001.  
[52] M. H. Crins, P. J. van der Wees, T. Klausch, S. A. van Dulmen, L. D. Roorda, and C. B. Terwee, 
"Psychometric properties of the PROMIS Physical Function item bank  in patients receiving physical 
therapy," PloS one, vol. 13, p. e0192187, 2018.  
[53] H. Pham, D. G. Armstrong, C. Harvey, L. B. Harkless, J. M. Giurini, and A. Veves, "Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial," 
Diabetes care, vol. 23, pp. 606- 611, 2000.  
[54] L. J. Tuttle, D. R. Sinacore, W. T. Cade, and M. J. Mueller, "Lower physical activity is associated with higher intermuscular adipose tissue in people with type 2 diabetes and peripheral neuropathy," Physical Therapy, vol. 91, pp. 923- 930, 2011.  
Study number:  s18-00527   Page 31 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  [55] P. D. Loprinzi and G. Pariser, "Physical activity intensity and biological markers among adults with 
diabetes: considerations by age and gender," Journal of Diabetes and its Complicati ons, vol. 27, 
pp. 134- 140, 2013.  
[56] E. L. Feldman, J. W. Russell, K. A. Sullivan, and D. Golovoy, "New insights into the pathogenesis of diabetic neuropathy," Current opinion in neurology, vol. 12, pp. 553 -563, 1999.  
[57] C. S. Andreassen, J. Jakobsen, S. Ringgaard, N. Ejskjaer, and H. Andersen, "Accelerated atrophy 
of lower leg and foot muscles --a follow -up study of long- term diabetic polyneuropathy using 
magnetic resonance imaging (MRI)," Diabetologia, vol. 52, pp. 1182- 91, Jun 2009.  
[58] M. J. Mueller,  S. D. Minor, S. A. Sahrmann, J. A. Schaaf, and M. J. Strube, "Differences in the gait 
characteristics of patients with diabetes and peripheral neuropathy compared with age- matched 
controls," Phys Ther, vol. 74, pp. 299- 308; discussion 309- 13, Apr 1994.  
[59] R. L. Kruse, J. W. LeMaster, and R. W. Madsen, "Fall and balance outcomes after an intervention to promote leg strength, balance, and walking in people with diabetic peripheral neuropathy:“feet 
first” randomized controlled trial," Physical therapy, vol. 90, pp. 1568- 1579, 2010.  
[60] C. D. Sartor, R. H. Hasue, L. P. Cacciari, M. K. Butugan, R. Watari, A. C. Passaro , et al., "Effects 
of strengthening, stretching and functional training on foot function in patients with diabetic neuropathy: results of a randomized controlled trial," BMC Musculoskelet Disord, vol. 15, p. 137, 
Apr 27 2014.  
[61] D. B. Northridge, S. Grant, I. Ford, J. Christie, J. McLenachan, D. Connelly , et al. , "Novel exercise 
protocol suitable for use on a treadmill or a bicycle ergometer," British heart journal, vol. 64, pp. 
313-316, 1990.  
[62] C. D. Sartor, R. Watari, A. C. Pássaro, A. P. Picon, R. H. Hasue, and I. C. Sacco, "Effects of a 
combined strengthening, stretching and functional training program versus usual -care on gait 
biomechanics and foot function for diabetic neuropathy: a randomized controlled trial," BMC musculoskeletal disorders, vol. 13, p. 36, 2012.  
[63] R. M. Baron and D. A. Kenny, "The moderator –mediator variable distinction in social psychological 
research: Conceptual, strategic, and statistical considerations," Journal of personality and social 
psychology, vol. 51, p. 1173, 1986.  
 
 
Study number:  s18-00527   Page 32 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authori zed in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  Attachments  
These documents are relevant to the protocol, but they are not considered part of the protocol.  They are 
stored and modified separately. As such, modifications to these documents do not require protocol amendments.  
 
 
Study number:  s18-00527   page 1    
Version: February 15, 2022  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by the s tudy sponsor  
Drug/Device Template Version: 13 JUN 2016  Attachment  A 
Schedule of Events  
Activity  Week 0  Week 1  Week 2 Week 3  Week 4  Week 5  Week 6  Week 7  Week 8  Week 9  
Consent   
X    
     
MNSI  X X         
Medical History  X     
     
Height /Weight   
X    
 X    
OGTT   X         
Biweekly Health 
Assessment     X  X     
VO 2R Assessment        X    
Plantar flexion training   X         
Bloodwork   
X    
     
Actigraph**   X X     X X  
MRI  
X    
X     
Aerobic exercise         X X X 
Resistance exercise         X X X 
PROMIS         X   
Calf muscle performance         X   
9-item physical 
performance test         X X X 
Blood Pressure (BP)         X X X 
**Actigraph to be worn for at least one week.  
 
  
Study number:  s18-00527   Page 2 
Version: February 15, 2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by the study sponsor  
Behavioral Intervention Template Version: 5 MAY 2017  Attachment  A 
Schedule of Events  Cont.…  
 
  
Activity  Week 10 Week 11 Week 12 Week 13 Week 14 Week 15 Week 16 Week 17 Week 18  
Consent        
   
MNSI          X 
Medical History        
   
Height /Weight        
 X  
OGTT          X 
Biweekly Health 
Assessment           
VO 2R Assessment         X  
Plantar flexion training           
Bloodwork        
  X 
Actigraph       X X   
MRI       
  X 
Aerobic exercise  X X X X X X X   
Resistance exercise  X X X X X X X   
PROMIS        X   
Calf muscle performance        X   
9-item physical performance 
test X X X X X X X   
Blood Pressure (BP)  X X X X X X X   